Entrada Therapeutics (TRDA) Retained Earnings (2020 - 2026)

Entrada Therapeutics' Retained Earnings history runs 7 years deep, the most recent figure standing at -$312.8 million for Q1 2026.

• On a quarterly basis, Retained Earnings fell 113.23% year-over-year to -$312.8 million in Q1 2026; TTM through Mar 2026 was -$312.8 million, a 113.23% decrease from a year earlier, with the FY2025 full-year figure at $652000.0, up 100.5% from the prior year.
• Retained Earnings retreated to -$312.8 million in Q1 2026 per TRDA's latest filing, from $652000.0 in the prior quarter.
• Across five years, Retained Earnings topped out at $441.1 million in Q1 2024 and bottomed at -$312.8 million in Q1 2026.
• The 5-year median for Retained Earnings is $621000.0 (2025), against an average of $111.8 million.
• Across the five-year window, Retained Earnings soared 27800.98% in 2023 and sank 66430.26% in 2024, its largest moves.
• Year by year, Retained Earnings stood at $402.9 million in 2022, then sank by 99.95% to $195000.0 in 2023, then sank by 66430.26% to -$129.3 million in 2024, then jumped by 100.5% to $652000.0 in 2025, then sank by 48077.15% to -$312.8 million in 2026.
• Per Business Quant, the three latest TRDA Retained Earnings figures stand at -$312.8 million (Q1 2026), $652000.0 (Q4 2025), and $621000.0 (Q3 2025).